(Press-News.org) Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice. Among them is the REC-CAGEFREE II trial.
Background and methods
The REC-CAGEFREE II trial is an open-label, investigator-initiated, non-inferiority, multicentre randomised trial comparing stepwise de-escalation of dual antiplatelet therapy (DAPT) with standard DAPT in patients with acute coronary syndrome (ACS) treated with paclitaxel-coated balloons (PCB). Eligible patients were randomly assigned to stepwise DAPT de-escalation − consisting of aspirin plus ticagrelor for 1 month, followed by 5 months of ticagrelor monotherapy, and then 6 months of aspirin monotherapy − compared to standard DAPT (aspirin plus ticagrelor for 12 months). The primary efficacy endpoint was net adverse clinical events (a composite of all-cause death, stroke, myocardial infarction [MI], revascularisation, and Bleeding Academic Research Consortium [BARC] type 3 or 5 bleeding) at 1 year.
Results
A total of 1,948 patients were enrolled and randomised to stepwise DAPT de-escalation (n=975) or standard DAPT (n=973). The study shows that stepwise DAPT de-escalation was non-inferior to standard 12-month DAPT for the primary endpoint in patients with ACS treated exclusively with PCB (87 [9.0%] vs 84 [8.7%]; difference: 0.3%, upper boundary of the one-sided 95% confidence interval [CI]: 2.4%; p non-inferiority=0.01). The rates of BARC type 3 or 5 bleeding were 0.4% and 1.7% (difference: −1.24%, 95 % CI: −2.14 to −0.33), and the rates of the composite of all-cause death, stroke, MI, and revascularisation were 8.8% and 7.6% (difference: 1.03%, 95 CI%: −1.40 to 3.47) in the stepwise de-escalation and standard groups, respectively.
Key learnings
The major strength of this study is that it provides the first randomised evidence regarding antiplatelet therapy strategy in drug-coated balloon (DCB) percutaneous coronary intervention (PCI). One of the potential advantages of using DCB is the need for shorter duration DAPT, given the lack of stent struts requiring endothelialisation. However, patients with ACS have higher ischaemic risk, and current guidelines still recommend DAPT for 12 months in patients without high bleeding risk.
The present study supports the value of de-escalation therapy with ticagrelor in ACS patients treated with DCB. However, some important considerations remain. First, evidence for the use of DCB in the context of de novo lesions (particularly in patients with ACS) is quite limited, with no randomised data to demonstrate adequate results in this context. Second, only around 40% of subjects underwent PCI for ST-elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI), while the rest had unstable angina. Application of the results to higher-risk patients with STEMI or NSTEMI is therefore debatable. Third, only 9% of all eligible patients were enrolled, indicating a very selected population. The main reason for exclusion was use of a drug-eluting stent (DES) in another vessel, raising concerns about the feasibility of a PCB-only strategy in patients with ACS, who often have multivessel disease, and the external validity of the data. Fourth, with regard to the procedure, only PCB were used, and 60% of the lesions treated were in small vessels (mean PCB diameter: 2.7 mm). In most patients, only one lesion was treated, again suggesting a very selected, low-risk population. Finally, several types of PCB were used, mostly without robust clinical evidence for their use in de novo lesions. There is no class effect for these devices, whose efficacy is influenced by multiple factors such as dose, formulation and release kinetics.
Conclusions and PCR recommendations
REC-CAGEFREE II is a pioneering study that provides the first randomised data concerning the use of antiplatelet therapy in the context of DCB. The results, however, are probably only applicable to low-risk populations (mainly those with unstable angina with single small vessel disease). Using DCB in the context of ACS poses theoretical advantages, including recovery of endothelial function and the lack of delayed endothelialisation and late acquired malapposition. These potential benefits require testing in adequately designed trials comparing the use of DCB in de novo lesions in ACS patients to DES (the current standard of care).
NOTES TO EDITORS
Key information
Session: Hotline/Late-Breaking Trials: Major Late-Breaking Trials from EuroPCR 2024
Presentation: One-month DAPT followed by 5-month Ticagrelor monotherapy in acute coronary syndromes with DCB
Presenter: Ling Tao
Palais des Congrès Porte Maillot – Paris, France
Wednesday 15 May 2024 – presentation time 08:30 CEST (session time 08:30-10:00) – Theatre Bleu
About EuroPCR 2024
The World-Leading Course in interventional cardiovascular medicine and the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) will take place from 14 to 17 May 2024, onsite at the Palais des Congrès, Paris, France. A digital package is also available for those unable to join in person.
The detailed Course Programme is available on: https://www.pcronline.com/Courses/EuroPCR/Programme
About PCR
The mission of PCR is to serve the needs of each individual patient by helping the global cardiovascular community to share knowledge, experience and practice. PCR offers a large range of many other educational meetings and resources for the continuing education of the interventional cardiovascular community. These include major annual courses across the globe, e-learning with high-profile PCR Webinars, courses specifically dedicated to valvular heart disease, tailor-made PCR Seminars on specific topics, online resources and medical publications such as EuroIntervention, the official journal of the EAPCI.
Gateways to all PCR activities are available on www.pcronline.com
For further information, please contact Sally Collingridge: scollingridge@europa-group.com
About the EAPCI
The European Association of Percutaneous Cardiovascular Interventions (EAPCI) is a branch of the European Society of Cardiology. Its mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions. This dynamic association represents a large community of over 8K EAPCI associates and over 1K full EAPCI members by helping them remain up to date in the constantly evolving field of PCI by publishing research and providing educational, training and certification programmes. The EAPCI also advocates for the best possible access to life saving treatments for patients through data-based advocacy at a European level.
HELP FOR JOURNALISTS TO COVER EUROPCR 2024
Register and attend EuroPCR 2024 as a journalist
Open to accredited journalists, free of charge. Journalists must hold a valid press card and/or provide a letter of assignment from a recognised publication. To register as press, go to
https://www.pcronline.com/Courses/EuroPCR/Press
EuroPCR press releases can be found at
https://www.pcronline.com/News/PCR-Press-Releases
For any press-related enquiries, please contact
EuroPCR Press Coordinator, Isabelle Uzielli: iuzielli@europcr.com
END
EuroPCR 2024 – One-month DAPT followed by 5-month Ticagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II
2024-05-15
ELSE PRESS RELEASES FROM THIS DATE:
EuroPCR 2024 – Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial
2024-05-15
Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice. Among them is the LANDMARK trial.
Background and Methods
Key randomized controlled trials have compared surgical aortic valve replacement (SAVR) with transcatheter aortic valve implantation (TAVI) using one of two commercially available transcatheter heart valves (THVs) - ...
How does exercise benefit the brain?
2024-05-15
New research published in Aging Cell provides insights into how exercise may help to prevent or slow cognitive decline during aging.
For the study, investigators assessed the expression of genes in individual cells in the brains of mice. The team found that exercise has a significant impact on gene expression in microglia, the immune cells of the central nervous system that support brain function. Specifically, the group found that exercise reverts the gene expression patterns of aged microglia to patterns seen in young microglia.
Treatments that depleted ...
How will climate change affect the distribution of jellyfish and other gelatinous zooplankton in the Arctic Ocean?
2024-05-15
Gelatinous zooplankton, including jellyfish and other diverse, nearly transparent organisms, play important roles in marine ecosystems. Climate change is expected to significantly alter their populations and distributions. New research published in Limnology and Oceanography examines their fate in the Arctic Ocean, one of the fastest warming oceans on Earth.
Investigators coupled three-dimensional species distribution models with oceanographic variables from the Coupled Model Intercomparison Project Phase 6. The analyses allowed the team to identify gelatinous ...
Researchers identify new marker for breast cancer prognosis
2024-05-15
A protein called retinitis pigmentosa GTPase regulator interacting protein 1-like (RPGRIP1L) performs various functions that are important for development and for health throughout life, and mutations in the RPGRIP1L gene have been linked to different diseases. New research published in The FASEB Journal indicates that expression levels of the RPGRIP1L gene might serve as a new prognostic marker for individuals with invasive breast cancer.
When investigators examined breast tissue specimens from different women, they found that the ...
Can robot-inspired computer-assisted therapy benefit children with autism?
2024-05-15
A new study published in the Journal of Computer Assisted Learning introduces a novel Robot-Inspired Computer-Assisted Adaptive Autism Therapy (RoboCA3T) that leverages the natural affinity of children with autism spectrum disorder towards technology and robots.
RoboCA3T harnesses the potential of robot-assisted therapies by incorporating robot avatars and integrating them with computer-assisted therapies through a web-based solution.
When investigators assessed Childhood Autism Rating Scale scores before and after the intervention, ...
Does getting out and about in the community affect cognitive function?
2024-05-15
The extent of individuals’ mobility within their community—how much they get out and about—may be linked to their cognitive function, according to new research published in the Journal of the American Geriatrics Society.
In the study of 7,016 Black and white adults aged 52 years and older who completed various questionnaires, greater community mobility was significantly associated with better cognitive function, although the association was small.
Because higher atherosclerotic cardiovascular disease (ASCVD) risk is associated with both mobility limitations and cognitive decline, investigators ...
How do mindfulness, self-compassion, other-compassion, and need fulfillment affect satisfaction in midlife married couples?
2024-05-15
Many people practice mindfulness or self-compassion techniques in their everyday life as part of their normal self-care routine. Although many studies support the individual benefits of mindfulness and self-compassion, few have focused on romantic relationship outcomes. A new study published in Personal Relationships examined how mindfulness, self- and other-compassion, and need fulfillment relate to relationship and sexual satisfaction in midlife married couples.
The study involved survey results from 640 adults aged 40–59 years who were residing in Canada and were married.
Mindfulness is the nonjudgmental attention and awareness to present ...
Novel technique helps predict risk of a meniscus tear in the knee
2024-05-15
New research indicates that various features assessed through imaging tests can reveal an individual’s risk of developing meniscus tears, which is one of the most common knee injuries.
The study, which is published in the Journal of Orthopaedic Research, was based on the use of radiomics, which unveils imperceptible patterns in medical images. Investigators used magnetic resonance images from 215 people with intact menisci at the start of the study who had 4-year meniscal status data.
Over 4 years, 34 participants developed meniscus tears. Use of radiomics at the start of the study correctly classified 24 of these 34 cases and 172 of 181 controls with a sensitivity of 70.6% ...
Healthcare interpreters important for heart attack rehabilitation
2024-05-15
After a heart attack, foreign-born people are less likely to attend a relapse-preventing Heart School than native-born patients. But with access to a professional interpreter, participation increases. This was found in a study led by researchers at Linköping University, published in the journal IJC Heart & Vasculature.
“Our conclusion is that healthcare should always strive to provide professional interpreters. For foreign-born patients, access to interpreters was associated with participation in Heart School, and the education provided there seems to have a similar and positive effect on treatment goals for both foreign-born ...
More women on hospital teams mean better surgery outcomes
2024-05-15
A new paper in the British Journal of Surgery, published by Oxford University Press, finds that care in hospitals with higher surgery team sex-diversity was associated with better post-operative outcomes for patients.
In various industries, including business, finance, technology, education, and the law, many observers believe gender and sex-diversity is important not only for equity, but also because it enriches the output of teams because members of the team bring a variety of experiences and viewpoints to their jobs. However, there is limited evidence for the value of teams’ sex-diversity in healthcare. Most published reports have focused on individuals’ ...